CoChat
Sign Up
Cited by 336Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive ProcessesHealth and Well-being Studies

Efficacy of Duloxetine on Cognition, Depression, and Pain in Elderly Patients With Major Depressive Disorder: An 8-Week, Double-Blind, Placebo-Controlled Trial

Raskin, Joel, Wiltse, Curtis G., Siegal, Alan, Sheikh, Javaid, Xu, Jimmy, Dinkel, James J., Rotz, Benjamin T., Mohs, Richard C.·2007·American Journal of Psychiatry
DOI 10.1176/appi.ajp.164.6.900
Open this paper in CoChat — free account

Abstract

Objective: This study compared the effects of duloxetine, 60 mg/day, versus placebo on cognition, depression, and pain in elderly patients with recurrent major depressive disorder. Method: Patients were randomly assigned (2:1) to duloxetine, 60 mg/day (N=207), or placebo (N=104) for 8 weeks in a double-blind study. The primary outcome measure was a prespecified composite cognitive score composed of four individual tests. Secondary measures included the Geriatric Depression Scale, the Hamilton Depression Rating Scale, the Visual Analogue Scale assessing pain, and standard safety and tolerability assessments. Results: Patients had a median age of 72 years (range=65–90). Duloxetine demonstrated significantly greater improvement in the composite cognitive score versus placebo (least-squares mean change from baseline to endpoint: 1.95 versus 0.76), driven by improved verbal learning and memory. Duloxetine treatment showed significantly greater baseline-to-endpoint reductions in both Hamilton depression scale (–6.49 versus –3.72) and Geriatric Depression Scale (–4.07 versus –1.34) total scores compared with placebo. Hamilton depression scale response (37.3% versus 18.6%) and remission (27.4% versus 14.7%) rates at endpoint were significantly higher for duloxetine than for placebo. Duloxetine significantly improved Visual Analogue Scale scores for back pain and time in pain while awake versus placebo. Significantly fewer patients receiving duloxetine withdrew from the study because of lack of efficacy (2.9% versus 9.6%); the incidences of discontinuation due to adverse events were similar for duloxetine and placebo (9.7% versus 8.7%). Conclusions: Duloxetine improved cognition, depression, and some pain measures and was safe and well tolerated in elderly patients with recurrent major depressive disorder.

Integrity signals

Registry

Crossref · 10.1176/ajp.2007.164.6.900

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cited by

Sorted by citations

Related

Authors
Raskin, J., Wiltse, C. G., Siegal, A., Sheikh, J., Xu, J., Dinkel, J. J., Rotz, B. T., & Mohs, R. C.
Affiliations
  • Eli Lilly (Canada) (CA)
  • Weill Cornell Medical College in Qatar (QA)
ORCID
Venue
American Journal of Psychiatry
Publisher
American Psychiatric Association Publishing
Published
2007-06
Volume
164
Issue
6
Pages
900-909
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
DOI
10.1176/appi.ajp.164.6.900
OpenAlex
W2118984041
Cited by
336
References
0
Citations by year
2026: 8 · 2025: 11 · 2024: 12 · 2023: 13 · 2022: 11 · 2021: 9 · 2020: 10 · 2019: 26 · 2018: 16 · 2017: 15 · 2016: 25 · 2015: 29 · 2014: 22 · 2013: 17 · 2012: 25
FWCI
15.59
Type
journal article
Language
en
Open access
closed
Locations
  • American Journal of Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Social Sciences › Psychology › Clinical Psychology › Health and Well-being Studies
Keywords
duloxetine, major depressive disorder, elderly patients, cognitive function, depression, pain, back pain, verbal learning and memory, antidepressant efficacy, adverse events, treatment safety
MeSH terms
Duloxetine Hydrochloride, Age Factors, Aged, Antidepressive Agents, Back Pain, Cognition Disorders, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Humans, Male, Neuropsychological Tests, Pain, Pain Measurement, Placebos, Psychiatric Status Rating Scales, Thiophenes, Geriatric Assessment, Comorbidity, Treatment Outcome, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review